Introduction
============

The occurrence of febrile neutropenia in cancer patients should lead to cautious severity assessment in order to provide appropriate management and therefore improve prognosis \[[@B1]\]. Despite specific recommendations, febrile neutropenia is still associated with high morbidity and mortality \[[@B2]\] and elevated health-related costs. The underlying conditions associated with febrile neutropenia make patients more vulnerable. Cancer itself compromises survival \[[@B3]\], impairs innate and adaptative immunity, and patients have a higher chance of developing a nosocomial infection \[[@B4]\]. Therefore, severe infections are common in this population. To help physicians safely decide the site of care for patients with febrile neutropenia, criteria have been determined \[[@B5]\], and sensitive scoring systems have been validated to limit patients\' misclassification \[[@B6]\]. In this setting, Multinational Association for Supportive Care in Cancer (MASCC) criteria were developed to help physicians make decisions about the site of care and overall management of patients with febrile neutropenia. This score mainly relies on subjective criteria such as the evaluation of clinical symptoms and hydration state.

Sepsis, severe sepsis and septic shock were defined 15 years ago as a continuum of increasing severity of the host response to the pathogen \[[@B3]\] closely related to predisposition, organ failure and systemic response, and to the microorganism and site of infection \[[@B7]\]. Management of septic patients has significantly improved over the past decade as a result of consensus guidelines published by 11 scientific societies \[[@B8]-[@B10]\]. These recommendations have been widely disseminated, but detecting patients at risk remains a daily challenge in emergency medicine.

The presence of cancer may impair the prognosis of acute patients \[[@B8]\], including septic patients \[[@B11]\] visiting the emergency department (ED) \[[@B12]\]. Reports on the management of febrile neutropenia in EDs are scarce, retrospective and mainly single centre studies. Interestingly, a French survey based on declarative questionnaires reported that 1 out of 31 cancer teams involved emergency physicians in their organizational strategy to manage patients with febrile neutropenia \[[@B13]\]. As the incidence of sepsis has increased in the general population \[[@B14]\], more patients visit the ED for this reason \[[@B15]\] and this had led to a dramatic increase in number of cancer patients in this setting \[[@B16]\].

This study was carried out to describe the management of patients with febrile neutropenia in EDs and to determine how management complies with recommendations. The secondary objective was to determine the factors associated with adequate management.

Materials and methods
=====================

Study design and ethics
-----------------------

This was a prospective multicentre study carried out in 47 French EDs over a six-month period (4 February to 4 August, 2008). The inform consent from patients was required for this study. The study protocol and patient information procedures were approved by the institutional review board for the protection of human subjects of the Cochin Port-Royal (Paris, France).

Recruitment of patients
-----------------------

Patients were included if they were adults (\>18 years old) who presented at a participating ED with febrile neutropenia after myelotoxic treatment for cancer. Delay between last cytotoxic treatment and occurrence of febrile neutropenia was not pre-specified to enter the study. Definition of febrile neutropenia consisted of a white blood cell count less than 1,000/μL (or neutrophils \<500/μL), with a core temperature above 8.3°C (or \>38°C on two consecutive occasions). Patients who presented with febrile neutropenia in another setting or who refused to participate were not included in the study.

Procedure and data collection
-----------------------------

An investigator (SA) contacted by phone the team leader of each participating centre to describe the study and explain criteria for eligibility. Each team leader gave the information about this study to the ED team. The physician on duty invited eligible patients to participate and implemented the electronic form. As this was an observation study, data were collected on the basis of usual practices.

The characteristics of each participating centre were recorded, with special reference to the management of febrile neutropenia. Data collected for each patient included demographic characteristics, physical data and medical history focusing on cancer and outcome (discharge, admission, admission to an ICU, death).

Study objectives
----------------

The primary objective was to describe the management of patients with febrile neutropenia in EDs and to determine whether management complies with recommendations. The secondary objective was to determine the factors associated with adequate management.

Evaluation criteria in the guidelines were identified to accurately assess the primary end points. Patients with febrile neutropenia were divided into two groups: those with and those without severe sepsis or septic shock (SS/SSh).

Patients with SS/SSh were selected according to the following criteria \[[@B9],[@B17]\]: blood lactate more than 4 mmol/L, or low blood pressure before fluid challenge (systolic blood pressure \<90 mmHg or 40 mmHg below usual systolic blood pressure), or at least one organ dysfunction (pulse oxymetry \[SpO~2~\] \<95% with fraction of inspired oxygen \>0.5, blood creatinine \>176 μmol/L or oliguria, international normalised ratio \>2, bilirubinemia \>78 μmol/L, Glasgow Coma Scale \<15). Thrombopenia was excluded from the criteria because of the potential effect of chemotherapy on platelet counts. Patients without SS/SSh were identified as high risk or low risk according to the MASCC classification \[[@B6]\] (Table [1](#T1){ref-type="table"}). Of note, data that allowed determination of MASCC and presence of SS/SSh were collected at the bedside by attending physicians. Implementation of the database was not intended to help physicians detecting the severity of a patient\'s condition.

###### 

Classification according to the Multinational Association for Supportive Care in Cancer(MASCC) \[[@B6]\]

  ----------------------------------------------------------------------
  Variables                                   Points\
                                              (Low-risk if score \>20)
  ------------------------------------------- --------------------------
  Burden of illness                           

   Age \< 60 years                            2

   Outpatient status                          3

   No chronic obstructive pulmonary disease   4

   No previous fungal infection               4

  Clinical state at admission                 

   No or mild symptoms                        5

   Moderate symptoms                          3

   Systolic blood pressure \<90 mmHg          5

   No dehydration needing perfusion           3
  ----------------------------------------------------------------------

Implementation of the following guidelines was assessed. Management of patients with SS/SSh required for the 90 first minutes \[[@B9],[@B10]\]: (i) a dose regimen of adequate (broad-spectrum) intravenous antimicrobial therapy; (ii) fluid challenge (500 mL) if mean arterial blood pressure was less than 65 mmHg; (iii) lactate measurement; (iv) at least one blood culture; and (v) hospitalization. Management of patients without SS/SSh who were high risk according to MASCC criteria required \[[@B18]-[@B20]\]: (i) adequate intravenous antimicrobial agent (broad-spectrum beta-lactam with or without an aminoglycoside); (ii) no initiation of granulocyte-cell stimulating factor (G-CSF); and (iii) hospitalization. Management of patients without SS/SSh who were low-risk according to MASCC criteria required \[[@B18]-[@B20]\]: (i) adequate oral antimicrobial agent (quinolone or amoxicillin/clavulanate or cephalosporin); (ii) no initiation of G-CSF; and (iii) hospital discharge.

Patients were divided into two groups; those managed according to recommendations and those who were not, irrespective of initial severity. The two populations were compared to determine the factors associated with adequate management.

Statistical analysis
--------------------

Quantitative variables are described as the mean ± standard deviation or median (range) and quantitative variables as number and percent. The adequacy of management according to recommendations was determined for the two sub-groups using Pearson\'s chi-squared test or Fisher\'s exact test for qualitative variables and the Student\'s t test or Wilcoxon rank sum test for quantitative variables. All tests were two-sided. A *P*value of less than 5% were considered statistically significant. All statistical analyses were carried out using R software (Vienna University of Economics and Business, 1090 Vienna, Austria).

Results
=======

Emergency departments
---------------------

The 47 participating EDs were distributed across France and were representative of each metropolitan region. Thirteen (28%) centres were tertiary teaching hospitals, six (13%) were in the Paris area and 29 (60%) had a dedicated unit for cancer patients. The median number of hospital beds was 500 (range, 150 to 2900) and the median number of ED visits was 17,679 during the six months of the study (range, 3,000-39,045). A written procedure for the management of febrile neutropenia was present in 19 EDs (40%) and was formalised with oncologists/haematologists in 15 (32%). This procedure referred to protective isolation in 10 (21%), antimicrobial agents in 16 (34%) and growth factors in 5 (11%) EDs.

Study participants and febrile neutropenia
------------------------------------------

Among the 777,876 patients who visited the EDs during the study period, 198 fulfilled the inclusion criteria (mean age 61 ± 14 years, 116 (60%) male) corresponding to one case every 3,930 visits; all these patients accepted to participate (Figure [1](#F1){ref-type="fig"}). Thirteen centres included five patients or more (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}).

![**Flow chart of patients included in the study**.](cc8972-1){#F1}

###### 

Characteristics of participating centres

  -------------------------------------------------------------------------------------
  Variables                                                     Number (%)\
                                                                Mean (range)
  ------------------------------------------------------------- -----------------------
  Participating centres:                                        47

   Tertiary teaching hospitals                                  13 (27%)

   General community hospitals                                  35 (74%)

  Number of beds in hospital                                    500 (150-2,900)

  Number of ED visits during the study period                   17,679 (3,000-39,045)

  Number of included patients:                                  198

   Tertiary teaching hospitals                                  111 (56%)

   General community hospitals                                  87 (44%)

  Number of centres with ≥ 5 patients                           13 (27%)

  Written procedure for the management of febrile neutropenia   19 (40%)

  Formalised with oncologists/haematologists                    

   Protective isolation                                         15 (79%)

   Antimicrobial agents                                         10 (53%)

   Prescription of G-CSF                                        16 (84%)
  -------------------------------------------------------------------------------------

ED, emergency department; G-CSF, granulocyte-cell stimulating factor.

###### 

Details of location, activity, inclusions and dedicated unit for cancer patients in participating centres

  Hospital centres                                 Number of inclusions   Number of ED visits during study period   Presence of cancer unit   Management procedure for febrile neutropenia
  ------------------------------------------------ ---------------------- ----------------------------------------- ------------------------- ----------------------------------------------
  \(01\) Ain: CH Bourg-en-Bresse                   2                      15,500                                    Yes                       Yes
  \(03\) Allier: CH Vichy                          1                      15,700                                    No                        No
  \(06\) Alpes Maritimes: CHU Nice                 2                      34,300                                    Yes                       No
  \(07\) Ardèche: CH Annonay                       2                      11,000                                    No                        Yes
  \(07\) Ardèche: CH Aubenas                       1                      ND                                        Yes                       No
  \(09\) Ariège: CH Val d\'Ariège                  1                      13,200                                    No                        No
  \(13\) Bouches-du-Rhône: CH Martigues            3                      16,991                                    No                        No
  \(15\) Cantal: CH Aurillac                       2                      12,444                                    Yes                       No
  \(15\) Cantal: CH Mauriac                        1                      3,000                                     No                        No
  \(17\) Charente-Maritime: CH La Rochelle         3                      21,500                                    No                        No
  \(17\) Charente-Maritime: CH Rochefort sur mer   3                      10,500                                    ND                        ND
  \(19\) Corrèze: CH Tulles                        1                      9,000                                     No                        No
  \(22\) Côtes d\'Armor: CH St Brieuc              2                      22,500                                    Yes                       Yes
  \(24\) Dordogne: CH Périgueux                    2                      14,900                                    No                        Yes
  \(26\) Drôme: CH Valence                         5                      19,130                                    Yes                       Yes
  \(28\) Eure-et-Loire: CH Chartres                2                      19,336                                    Yes                       No
  \(35\) Ile-et-Vilaine: CH St Malo                1                      18,000                                    Yes                       Yes
  \(36\) Indre: CH Le Blanc                        1                      4,570                                     ND                        ND
  \(37\) Indre-et-Loire: CH Chinon                 3                      6,857                                     Yes                       Yes
  \(37\) Indre-et-Loire: CHU Tours                 8                      24,000                                    Yes                       Yes
  \(38\) Isère: CHU Grenoble                       5                      35,600                                    Yes                       Yes
  \(40\) Landes: CH Mont-de-Marsan                 5                      ND                                        Yes                       No
  \(42\) Loire: CHU St Etienne                     13                     20,232                                    Yes                       No
  \(44\) Loire Atlantique: CH Chateaubriant        1                      7,000                                     No                        No
  \(45\) Loiret: CH Montargis                      4                      15,222                                    Yes                       Yes
  \(45\) Loiret: CH Orléans                        6                      19,500                                    Yes                       No
  \(47\) Lot-et-Garonne: CH Agen                   1                      10,000                                    No                        No
  \(49\) Maine-et-Loire: CHU Angers                4                      23,882                                    Yes                       Yes
  \(54\) Meurthe-et-Moselle: CH Lunéville          1                      8,200                                     No                        No
  \(59\) Nord: CH Dunkerque                        6                      26,156                                    Yes                       Yes
  \(62\) Pas de Calais: CH St Omer                 1                      ND                                        ND                        ND
  \(63\) Puy de Dôme: CH Thiers                    1                      6,000                                     No                        No
  \(63\) Puy de Dôme: CHU Clermont Ferrand         4                      22,000                                    Yes                       No
  \(64\) Pyrénnées Atlantiques: CH Bayonne         2                      15,000                                    Yes                       Yes
  \(64\) Pyrénnées Atlantiques: CH Pau             2                      13,000                                    Yes                       No
  \(71\) Saône-et-Loire: CH Mâcon                  1                      17,025                                    Yes                       ND
  \(72\) Sarthre: CH Le Mans                       1                      28,643                                    Yes                       Yes
  \(75\) Paris: CHU Cochin                         22                     23,368                                    Yes                       Yes
  \(75\) Paris: CHU Hôtel Dieu                     3                      22,586                                    Yes                       Yes
  \(75\) Paris: CHU Pitié                          9                      39,045                                    Yes                       No
  \(75\) Paris: CHU Saint Antoine                  1                      23,710                                    Yes                       Yes
  \(75\) Paris: CHU Saint Louis                    38                     16,948                                    Yes                       Yes
  \(75\) Paris: CHU Tenon                          5                      22,261                                    No                        No
  \(79\) Deux Sèvres: CH Niort                     1                      17,700                                    Yes                       No
  \(81\) Tarn: CH Albi                             3                      14,587                                    No                        No
  \(91\) Essonne: CH Longjumeau                    6                      15,000                                    Yes                       Yes
  \(94\) Créteil: CHU Henri Mondor                 5                      22,783                                    Yes                       No

ED, emergency department, ND, not determined.

A solid neoplasm was reported in 111 patients (56%) and haematological cancer in 87 (44%). Seventy-four patients (39%) had an underlying disorder. Patients often self-referred to the ED (n = 87, 44%). Forty-seven (24%) patients were treated with G-CSF to prevent neutropenia and 174 (88%) had one or more risk factors that should have prompted the prophylactic use of G-CSF (Table [4](#T4){ref-type="table"}).

###### 

Prescription of G-CSF

  Variables                                                  Number (%)
  ---------------------------------------------------------- ------------
  Prophylactic prescription of G-CSF before referral in ED   47 (24)
  Age \>65 years                                             14 (30)
  Recurrent or resistant cancer                              28 (60)
  Chemotherapy at high-risk for neutropenia (risk \>20%)     15 (38)
  Previous history of febrile neutropenia                    15 (32)
  Prescription of G-CSF initiated in ED                      27 (19)
  Patients with severe sepsis                                12 (44)

ED, emergency department; G-CSF, granulocyte-cell stimulating factor.

The characteristics of the patients are summarised in Table [5](#T5){ref-type="table"}. Median delay between chemotherapy and ED visit was 10 days, ranging from 4 to 35 days. According to the criteria selected for disease severity, 89 (45%) patients had SS/SSh, 108 (55%) did not have SS/SSh and one could not be classified.

###### 

Characteristics of the patients

                                              Total population   Patients with severe sepsis   Patients without severe sepsis   *P*
  ------------------------------------------- ------------------ ----------------------------- -------------------------------- ---------
  Number of patients                          198                89                            108                              
  Age (years), mean ± SD                      61 ± 14            65 ± 13                       57 ± 14                          \<0.001
  Female, n (%)                               79 (41)            30 (34)                       49 (46)                          0.11
  Karnofsky index, median (range)             70 (30-100)        70 (30-100)                   80 (30-100)                      0.06
  Underlying disorders, n (%)                 73 (38)            36 (43)                       37 (35)                          0.32
   Chronic pulmonary disease                  9 (12)             6 (16)                        3 (3)                            
   Chronic heart failure                      12 (16)            9 (24)                        3 (3)                            
   Cirrhosis                                  7 (9)              4 (11)                        3 (3)                            
   Hemodialysis chronic renal failure         2 (3)              2 (5)                         0                                
   Severe neurological disorder               3 (4)              1 (3)                         2 (2)                            
   Other                                      51 (69)            21 (57)                       30 (29)                          
  Haematological neoplasm, n (%)              87 (44)            40 (45)                       47 (44)                          0.84
   Lymphoproliferation                        64 (32)            30 (34)                       34 (31)                          
   Myeloproliferation                         22 (11)            10 (11)                       12 (11)                          
   Undetermined                               1                  0                             1                                
  Solid cancer                                111 (56)           49 (55)                       61 (56)                          
   Lung                                       39 (20)            24 (27)                       15 (14)                          
   Breast                                     26 (13)            9 (10)                        17 (16)                          
   Urological and genital                     18 (9)             9 (10)                        9 (8)                            
   Gastro-intestinal                          13 (7)             5 (6)                         7 (6)                            
   Other or undetermined                      15 (8)             1                             8 (7)                            
  Presence of metastasis or uncontrolled      133 (67)           69 (78)                       63 (58)                          0.004
  Previous history of febrile neutropenia     60 (31)            24 (27)                       36 (35)                          0.32
  Chemotherapy at high-risk for neutropenia   36 (23)            15 (21)                       21 (25)                          0.57
  Corticosteroids                             83 (42)            37 (42)                       46 (43)                          0.89
  Prophylaxis with G-CSF                      47 (25)            18 (20)                       29 (28)                          0.22
  Antimicrobial therapy prior to ED           48 (25)            15 (17)                       33 (31)                          0.03
  MASCC \<20 (high-risk)                      105 (53)           67 (75)                       38 (35)                          \<0.001

Results are expressed as number (%), mean ± standard deviation (SD), or median (range). *P*values below 0.05 are statistically significant.

ED, emergency department; G-CSF, granulocyte-cell stimulating factor; MASCC, Multinational Association for Supportive Care in Cancer.

Among the 89 patients with SS/SSh, ED physicians recognised the severity signs in 45 (55%). Blood cultures were obtained from 87 (98%) patients and lactate concentration was measured in 29 (32%). Antimicrobial therapy with a broad-spectrum beta-lactam was started within 90 minutes in 19 of 86 (22%) patients (data missing for three). Among these patients, nine (10%) also received an aminoglycoside. Appropriate fluid challenge was given to 43 (49%) patients and 88 were hospitalised (99%), including 18 who were admitted to the ICU. Only six (7%) patients with SS/SSh received adequate management (Table [6](#T6){ref-type="table"}). Of note, G-CSF was initiated in the ED in 12 patients (14%) with SS/SSh.

###### 

Characteristics of the management of febrile neutropenia in patients with or without severe sepsis

  Management in the ED             Patients with severe sepsis   Patients without severe sepsis   
  -------------------------------- ----------------------------- -------------------------------- ---------
  Adequate antimicrobial therapy   28 (32)                       30 (81)                          31 (44)
  Supportive treatment                                                                            
   Fluid challenge                 43 (49)                       5 (14)                           6 (9)
   Vasoactive drugs                6 (7)                         0 (0)                            0 (0)
  Laboratory data                                                                                 
   Lactate concentration           29 (33)                       1 (3)                            11 (16)
   Blood cultures                  87 (99)                       36 (100)                         63 (93)
  New prescription of G-CSF        12 (14)                       4 (11)                           12 (17)
  Adequate orientation             88 (99)                       35 (95)                          6 (9)
  Global adequate management       6 (7)                         26 (68)                          1 (1)

Risk of patients without severe sepsis was determined using MASCC criteria (low risk if MASCC ≥ 20; high risk if MASCC \<20). All results are expressed as number (%). ED, emergency department; G-CSF, granulocyte-cell stimulating factor; MASCC, Multinational Association for Supportive Care in Cancer.

There were 108 patients without SS/SSh: 38 were high risk (35%) and 70 were low risk (65%) according to MASCC criteria. In the high-risk category, adequate antimicrobial therapy was given to 31 (81%) patients, G-CSF was initiated in the ED in four (10%) and 35 (95%) were hospitalised. In the low-risk category, four (6%) patients received an adequate oral antimicrobial agent, but an IV antimicrobial agent was prescribed in 59 (84%) cases. G-CSF was initiated in the ED in 12 (17%) patients. Only six patients (9%) were discharged; the remaining patients were believed to have been admitted. Adequate management was proposed in 27 of 108 (25%) patients without SS/SSh, 26 (68%) high-risk patients and one low-risk patient (Table [2](#T2){ref-type="table"}).

The 33 (17%) patients who were given adequate management were compared with the 161 (83%) patients managed inadequately (important data were missing in four patients that were excluded from the analysis). Patients without SS/SSh were significantly more likely to receive adequate management than those with SS/SSh (*P*= 0.00009). On the other hand, adequate management was proposed in 32 of 103 high-risk patients (31%) whereas only 1 low-risk patient out of 91 (*P*\< 0.0001) was treated according to recommendations (Table [7](#T7){ref-type="table"}).

###### 

Factors associated with adequate management

  ----------------------------------------------------------------------------------------------------------------------------------
  Variables                                                                Adequate management\   Inadequate management\   *P*
                                                                           (n = 33)               (n = 161)                
  ------------------------------------------------------- ---------------- ---------------------- ------------------------ ---------
  Tertiary teaching hospital                              Yes              24 (12)                92 (88)                  0.1

                                                          No               9 (21)                 68 (79)                  

  Number of ED visits during study period                 \<20 000         17 (18)                78 (82)                  0.80

                                                          ≥ 20 000         15 (16)                76 (84)                  

  Unit for cancer patients                                Yes              29 (18)                132 (82)                 1

                                                          No               4 (15)                 22 (85)                  

  Written procedures for febrile neutropenia management   Yes              24 (21)                92 (79)                  0.16

                                                          No               9 (13)                 62 (87)                  

  Age (mean ± SD)                                                          58 ± 17                61 ± 14                  0.30

  Sex                                                     Male             17 (15)                97 (85)                  0.29

                                                          Female           16 (21)                61 (79)                  

  Karnosfsky index (median (range))                                        70 (30-100)            80 (30-100)              0.07

  Place of stay                                           Home             30 (18)                139 (82)                 0.23

                                                          House care       2 (40)                 3 (60)                   

  Underlying disorder                                     Yes              12 (17)                60 (83)                  0.78

                                                          No               21 (18)                94 (82)                  

  Type of cancer                                          Haematological   14 (17)                70 (83)                  0.91

                                                          Solid cancer     19 (17)                91 (83)                  

  Presence of metastasis or uncontrolled                  Yes              22 (17)                108 (83)                 0.96

                                                          No               11 (17)                53 (83)                  

  Antimicrobial therapy prior to ED                       Yes              9 (9)                  39 (91)                  0.75

                                                          No               24 (17)                119 (83)                 

  Time of ED visit                                        Day              18 (15)                102 (85)                 0.24

                                                          Night            15 (22)                54 (78)                  

  Level of nurse triage                                   \<3              20 (22)                73 (78)                  0.43

                                                          ≥ 3              8 (16)                 42 (84)                  

  Presence of severity signs according to ED physician    Yes              9 (17)                 45 (83)                  0.82

                                                          No               24 (18)                109 (82)                 

  Severe sepsis                                           Yes              6 (7)                  80 (93)                  0.0009

                                                          No               27 (25)                81 (75)                  

  Cancer specialist advice                                Yes              14 (17)                70 (83)                  0.95

                                                          No               18 (17)                88 (83)                  

  MASCC classification                                    High risk        32 (31)                71 (69)                  \<0.001

                                                          Low risk         1 (1)                  90 (99)                  

  Protective isolation                                    Yes              29 (19)                128 (81)                 0.50

                                                          No               4 (13)                 26 (87)                  

  Surgical management                                     Yes              2 (50)                 2 (50)                   0.12

                                                          No               26 (15)                146 (85)                 

  Adequate orientation                                    Agree            26 (17)                129 (83)                 0.65

                                                          Disagree         7 (20)                 28 (80)                  
  ----------------------------------------------------------------------------------------------------------------------------------

Values shown are number and percentage unless stated otherwise. *P*values below 0.05 are statistically significant.

ED, emergency department; G-CSF, granulocyte-cell stimulating factor; MASCC, Multinational Association for Supportive Care in Cancer; SD, standard deviation.

Discussion
==========

The results of this study suggest that cancer patients with febrile neutropenia visiting the ED are likely to present with SS/SSh, and their management does not comply with current guidelines especially in those with more severe infections.

The 47 participating centres were distributed across France and presented heterogeneous characteristics. This was representative of French EDs overall. As only 60% of hospitals had a dedicated cancer unit, it was assumed that cancer patients with febrile neutropenia visited community hospitals with this acute adverse event. This suggests that procedures to treat these patients should be available in every ED. However, only 40% of participating centres reported a written protocol for the management of febrile neutropenia. A total of 198 consecutive patients with febrile neutropenia were included in the study. The demographic characteristics of these patients corresponded to epidemiologic data published by the French Institute Survey for cancer \[[@B16]\].

EDs are first dedicated to the management of patients with severe disorders including severe infections. A recent study reported that SS/SSh accounted for more than 500,000 visits annually in US EDs \[[@B21]\]. In addition, the incidence of severe sepsis is increasing \[[@B22]\], cancer is a predisposing factor for sepsis, and the number of cancer patients will almost double within one decade \[[@B23]\]. Optimising prevention of febrile neutropenia is therefore an important part of the management. Forty-seven (24%) patients were treated with G-CSF to prevent febrile neutropenia, whereas 174 (88%) had one or more risk factors that should have prompted the prophylactic use of G-CSF \[[@B24]\]. In our sample, there was an under-use of G-CSF in patients at risk of febrile neutropenia. The under-use of G-CSF in oncology practice was also reported previously by Hayes \[[@B25]\]. We therefore believe that emergency physicians will have increasing chances to treat febrile neutropenia.

In their series used to derive and validate the Mortality in Emergency Department Sepsis (MEDS) score, Shapiro and colleagues reported that 35.5% and 2.5% of patients visiting the ED with infection had severe sepsis and septic shock, respectively \[[@B12]\]. Here we reported that 89 (45%) patients with febrile neutropenia presented with SS/SSh. This underscores that chemotherapy-related neutropenia in cancer patients is a risk factor for developing severe infection. In our series, very few patients that developed severe infections were treated according to current guidelines. Indeed, adequate management was initiated in only six patients. This may suggest that detecting severe infections is challenging for emergency physicians. Initial severity assessment is sometimes falsely reassuring and patients may worsen during their stay in the ED \[[@B26]\]. A study conducted in Brazil \[[@B14]\] reported that ED physicians were able to detect severe infection in 15.8% of cases. Implementation of the Surviving Sepsis Campaign guidelines improved detection of severe infections but 61.5% of patients remained under-treated because of inadequate assessment. Measuring lactate concentration has been recommended to help physicians detect \[[@B26]\] and manage severe infections \[[@B27]\]. We observed that lactate was infrequently measured in the present series. Therefore, procedures to optimise detection of severe infection were partially applied in our patients that did not seem to be perceived as severely ill.

A burden of evidence supports the paramount role of early recognition and prompt management of severe infection, and admission to the ICU when applicable \[[@B27]\]. The prognosis of patients with severe infection actually depends on their initial management; that is, treatment received in the ED for half of patients \[[@B28]\]. We observed that few patients received adequate antimicrobial therapy or fluid challenge in an appropriate time-span. We therefore conclude that patients with severe infection were under-treated. Similar findings were reported in a large Spanish study \[[@B29]\], as an incredibly low rate of patients admitted with SS/SSh received process-of-care according to bundles, even after an educational program involving physicians and nurses of the ED and ICU. An inadequate initial assessment may result from difficulties to correctly implement guidelines in a busy ED. First, equipment and physicians\' skills to provide complex technical procedures to patients vary betwen hospitals \[[@B30]\]. Barriers can also be related to time consumption of procedures necessary to implement procedures for severe infections. In addition, all team leaders are not fully confident in guidelines to treat severe infections \[[@B31]\]. However, we checked fluid loading and delay to first antimicrobial agent that do not require specific skills or organisation. We observed that these basic treatments were not correctly delivered. In a series of sepsis with hypotension, the delay to antimicrobial agents was over six hours in more than half of patients because infection was not recognised. We believe that most patients were not treated according to guidelines because initial assessment failed to detect the severity of disease.

Despite the efforts in the past decade to produce and distribute specific guidelines for treating severe infection, difficulties persist to detect SS/SSh even in typically at-risk patients such as those with febrile neutropenia.

Delay to first antimicrobial agent has an impact on prognosis in patients presenting infection with severity criteria \[[@B32]\]. Guidelines to treat patients with SS/SSh endorse that first dose of antibiotics should be given in a timespan shorter than 90 minutes \[[@B9]\]. Whereas it can be assumed that earlier antimicrobial agents would improve prognosis in febrile neutropenia, no evidence can currently lead to any recommendations about delay. Consequently, guidelines to treating patients with febrile neutropenia are not clear regarding delays to treatment; therefore, objectives are easier to obtain. This may partly explain why management of patients without SS/SSh frequently reached goals.

A puzzling result is that supportive care was not modified by the intervention of the oncologist or haematologist: the presence of a medical unit dedicated to cancer in the same hospital, the existence of written procedures about febrile neutropenia, or the oncologist\'s advice did not improve the quality of care. Despite recent validation studies, the relevance of MASCC to guide site of care can be limited because several cornerstone items are missing from this evaluation tool \[[@B18]\]. This supports the fact that the assessment of severity of infection in a short time-span appears to be particularly challenging in onco-haematological patients \[[@B33]\].

The study has several limitations. Whereas simplicity of the study design presumably improved acceptability and feasibility, we cannot rule out that patients could be missed because making clinical research around the clock is sometimes difficult in busy EDs. Our study did not follow up the patients. It was decided to carry out a descriptive study and patients\' outcomes were not recorded. Thus, it is unknown whether the prognosis of the patients with febrile neutropenia would have changed if recommendations had been implemented. In addition, the study was proposed to 350 French hospitals, but only 47 took part. Therefore, results could have been biased because EDs that participated were possibly more involved in the management of patients with sepsis and/or cancer. However, these centres were geographically distributed across France and were representative of French EDs because they were mostly set in general hospitals. In addition, only 19 Eds had a written procedure for febrile neutropenia. The convenience series was also limited because no patient waived the invitation to participate in this prospective study. Another limitation was the use of MASCC criteria to decide on the site of care and antimicrobial therapy because this score has never been validated in the ED setting. Stratification of patients using the MASCC scoring system is debatable as consensus meetings suggest that it is not superior to expert advice. However, the MASCC classification has been regularly used as a gold standard to stratify patients with febrile neutropenia. In addition MASCC calculation depends on the burden of the onco-haematological disorder. However, it is usually accepted that patients with advanced cancer under-estimate the severity of the disorder \[[@B34],[@B35]\]. As emergency physicians usually obtain past medical history from patients\' interviews, they may misclassify severity of febrile neutropenia when assessed by MASCC level. Finally, we found that patients with more severe and mild febrile neutropenia were inadequately treated according to a univariate analysis. We were unable to identify risk factors for inadequate management by a multivariate analysis, partly because of the size of the sample.

Conclusions
===========

Patients with febrile neutropenia who visit the EDs are likely to develop severe infection. In this sample, patients who met our definition of SS/SSh had a low rate of being treated with adequate fluid and a low rate of evaluation with serum lactate level. Patients who were considered to be low risk were often admitted to the hospital rather than being discharged home on oral antibiotics. More work is needed within the standard operation protocols of EDs as well as outcome-based research to optimise care for these patients.

Key messages
============

• Patients with febrile neutropenia are likely to present to the ED with severe infections.

• More severe patients are poorly recognised and under-treated.

• Patients with mild disorders are over-treated.

• Patients with febrile neutropenia presenting to the ED are usually not treated according to guidelines.
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ED: emergency department; G-CSF: granulocyte-cell stimulating factor; MASCC: Multinational Association of Supportive Care in Cancer; SS: severe sepsis; SSh: septic shock.
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